BioSpace News Archive

BriaCell Therapeutics Corp. is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022.

An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it has reached an agreement to acquire Apotex Pharmaceutical Holdings Inc.

Zhongchao Inc. announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd. which mainly engages in pharmaceutical import and export trade, OME production, medical consumables operation, and pharmaceutical internet services.

Ludwig Enterprises , a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce more detail on this crucial technology, cooperative contracts, and current applications.

Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its leading role in the USD68m series A financing of Pheon Therapeutics (Pheon), that has emerged from stealth today.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that its board of directors (the “Board”) has appointed Philip Lambert, Ph.D., as Chief Technology Officer (“CTO”) of the Company, effective September 27, 2022.

Gradalis today announced that it will host a key opinion leader (KOL) webinar on the current treatment landscape for ovarian cancer and Vigil ® , the company’s fully personalized, patient-specific cancer immunotherapy, on Monday, October 3, 2022 at 1:00 p.m. ET.

Evommune, Inc. today announced enrollment of the first patient in a Phase 2a proof-of-concept clinical trial evaluating EVO101, a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), in patients with atopic dermatitis (AD).

Advanced Instruments today announced the launch of Solentim VIPS PRO, a high efficiency single cell seeder, at the BioProcess International Conference in Boston, Massachusetts.